🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42 Clear sponsor filter
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
42 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 6)
2024-520445-23-00Overweight or obesity, and knee osteoarthritis
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Poland, Spain, Bulgaria, Italy, Denmark
07/04/2026
Phase I
A research study looking into how cagrilintide influences food intake and appetite in people with overweight or obesity
2025-524206-15-00Obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
02/04/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure (AMAZE 3)
2024-520442-36-00Overweight or obesity, and obstructive sleep apnoea not tre…
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark, Poland, Spain, Germany
30/03/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure (AMAZE 4)
2024-520443-16-00Overweight or obesity, and obstructive sleep apnoea treated…
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Poland, Spain, Germany
24/03/2026
Phase I
A research study looking at how NNC0487-0111 affects food intake, appetite and metabolism after meals in people with obesity
2025-521393-34-00Participants with obesity, but otherwise healthy
Novo Nordisk A/S
Not possible to specify
Germany
13/03/2026
Phase I
Investigating how NNC0487-0111 regulates insulin in adults with type 2 diabetes
2025-521595-55-00Type 2 Diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
09/03/2026
Phase I
Understanding the effect of CagriSema, cagrilintide, and semaglutide on muscle health
2025-522920-28-00Obesity, CCI, CCI
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark
06/03/2026
Phase I/II
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease
2024-519881-32-00Sickle Cell Disease
Novo Nordisk A/S
Hemic and Lymphatic Diseases
France
06/02/2026
Phase I
A study understanding how much CDR132L enters the bloodstream after injection under the skin compared to injection into a vein in healthy participants
2025-521329-34-00Healthy volunteers, treatment for heart failure
Novo Nordisk A/S
Cardiovascular Diseases
Germany
26/01/2026
Phase III
A 40-week study comparing the efficacy, safety and patient-reported outcomes of once weekly IcoSema and once or twice daily insulin degludec/insulin aspart 100 units/mL, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily pre-mixed insulin. COMBINE 5
2025-521150-42-00Type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Poland
09/12/2025
Phase III
CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).
2024-518899-31-00Variant or wild-type transthyretin (TTR) amyloid cardiomyop…
Novo Nordisk A/S
Cardiovascular Diseases
Germany, France, Belgium, Italy, Denmark, Netherlands, Spain, Czechia
09/12/2025
Phase I
A research study of a new medicine NNC0363-1063 in participants with type 1 diabetes
2025-521593-33-00Diabetes type 1
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
20/11/2025
Phase III
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes
2024-519531-41-00Overweight and obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Czechia, Romania, Croatia, Slovakia, Hungary
29/10/2025
Phase I
A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes
2024-519382-22-00Healthy Participants and Participants with type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
24/10/2025
Phase III
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity
2024-519530-24-00Overweight and obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Norway, France, Italy, Germany, Poland
07/10/2025
Phase I
A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A
2025-520490-38-00Haemophilia A with or without inhibitors. Proposed indicati…
Novo Nordisk A/S
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Poland, Spain, Austria, Italy, Germany, Belgium, France, Portugal, Sweden
22/09/2025
Phase IV
EFFectiveness of once-weekly insulin ICodec versus once-daily basal Insulin analogues in an insulin-naïve type 2 diabEtes population in real-world cliNical pracTice- The EFFICIENT pragmatic study
2024-520068-32-00Type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany, Italy
05/09/2025
Rows per page Showing 26–42 of 42
Previous 1 2
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.